Page 133 - 中国全科医学2022-14

·1794· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

2020，34（2）：101418. DOI：10.1016/j.beem.2020.101418. DOI：10.1007/s11060-018-2844-2.
［24］PEREZ-RIVAS L G，THEODOROPOULOU M，FERRAÙ F， ［37］KEMENY H R，ELSAMADICY A A，FARBER S H，et al.
et al. The gene of the ubiquitin-specific protease 8 is frequently Targeting PD-L1 initiates effective antitumor immunity in a murine
mutated in adenomas causing Cushing's disease［J］. J Clin model of cushing disease［J］. Clin Cancer Res，2020，26（5）：
Endocrinol Metab，2015，100（7）：E997-1004. DOI：10.1210/ 1141-1151. DOI：10.1158/1078-0432.CCR-18-3486.
jc.2015-1453. ［38］LIN A L，JONSSON P，TABAR V，et al. Marked response of a
［25］FOULKES E，NEWELL-PRICE J. New molecular targets for hypermutated ACTH-secreting pituitary carcinoma to ipilimumab
treatment of Cushing's disease［J］. Endocrinol Metab Clin North and nivolumab［J］. J Clin Endocrinol Metab，2018，103（10）：
Am，2018，47（2）：367-373. DOI：10.1016/j.ecl.2018.02.006. 3925-3930. DOI：10.1210/jc.2018-01347.
［26］FUKUOKA H，COOPER O，BEN-SHLOMO A，et al. EGFR as a ［39］CACCESE M，BARBOT M，CECCATO F，et al. Rapid disease
therapeutic target for human，canine，and mouse ACTH-secreting progression in patient with mismatch-repair deficiency pituitary
pituitary adenomas［J］. J Clin Invest，2011，121（12）：4712- ACTH-secreting adenoma treated with checkpoint inhibitor
4721. DOI：10.1172/jci60417. pembrolizumab［J］. Anticancer Drugs，2020，31（2）：199-
［27］SESHACHARYULU P，PONNUSAMY M P，HARIDAS D， 204. DOI：10.1097/cad.0000000000000856.
et al. Targeting the EGFR signaling pathway in cancer ［40］SCHRECK K C，GROSSMAN S A. Role of temozolomide in the
therapy［J］. Expert Opin Ther Targets，2012，16（1）：
treatment of cancers involving the central nervous system［J］.
15-31. DOI：10.1517/14728222.2011.648617.
Oncology：Williston Park，2018，32（11）：555-560，569.
［28］ASARI Y，KAGEYAMA K，SUGIYAMA A，et al. Lapatinib
［41］SHEEHAN J，RAINEY J，NGUYEN J，et al. Temozolomide-
decreases the ACTH production and proliferation of corticotroph
induced inhibition of pituitary adenoma cells［J］. J Neurosurg，
tumor cells［J］. Endocr J，2019，66（6）：515-522. DOI：
2011，114（2）：354-358. DOI：10.3171/2010.4.jns1024.
10.1507/endocrj.ej18-0491.
［42］RAVEROT G，CASTINETTI F，JOUANNEAU E，et al. Pituitary
［29］CIATO D，ALBANI A. Molecular mechanisms of glucocorticoid
carcinomas and aggressive pituitary tumours：merits and pitfalls of
resistance in corticotropinomas：new developments and drug targets
temozolomide treatment［J］. Clin Endocrinol：Oxf，2012，76（6）：
［J］. Front Endocrinol：Lausanne，2020，11：21. DOI：
769-775. DOI：10.1111/j.1365-2265.2012.04381.x.
10.3389/fendo.2020.00021.
［43］BROSSAUD J，PALLET V，CORCUFF J B. Vitamin A，endocrine
［30］RIEBOLD M，KOZANY C，FREIBURGER L，et al. A C-terminal
tissues and hormones：interplay and interactions［J］. Endocr
HSP90 inhibitor restores glucocorticoid sensitivity and relieves a
Connect，2017，6（7）：R121-130. DOI：10.1530/ec-17-
mouse allograft model of Cushing disease［J］. Nat Med，2015，
0101.
21（3）：276-280. DOI：10.1038/nm.3776.
［44］CASTILLO V，GIACOMINI D，PA'EZ-PEREDA M，et al.
［31］SHEN Y，JI C，JIAN X，et al. Regulation of the EGFR pathway
Retinoic acid as a novel medical therapy for Cushing's disease in
by HSP90 is involved in the pathogenesis of Cushing's disease［J］.
dogs［J］. Endocrinology，2006，147（9）：4438-4444. DOI：
Front Endocrinol：Lausanne，2020，11：601984. DOI：10.3389/
10.1210/en.2006-0414.
fendo.2020.601984.
［45］PECORI GIRALDI F，AMBROGIO A G，ANDRIOLI M，et al.
［32］SALLER R，MEIER R，BRIGNOLI R. The use of silymarin in the
Potential role for retinoic acid in patients with Cushing's disease［J］.
treatment of liver diseases［J］. Drugs，2001，61（14）：2035-
J Clin Endocrinol Metab，2012，97（10）：3577-3583. DOI：
2063. DOI：10.2165/00003495-200161140-00003.
10.1210/jc.2012-2328.
［33］SALMANINEJAD A，VALILOU S F，SHABGAH A G，
［46］VILAR L，ALBUQUERQUE J L，LYRA R，et al. The role of
et al. PD-1/PD-L1 pathway：Basic biology and role in cancer
isotretinoin therapy for Cushing's disease：results of a prospective
immunotherapy［J］. J Cell Physiol，2019，234（10）：16824-
study［J］. Int J Endocrinol，2016，2016：8173182. DOI：
16837. DOI：10.1002/jcp.28358.
10.1155/2016/8173182.
［34］HOFMEYER K A，JEON H，ZANG X X. The PD-1/PD-L1 （B7-
［47］ZHANG D，DU L，HEANEY A P. Testicular receptor-4：novel
H1） pathway in chronic infection-induced cytotoxic T lymphocyte
exhaustion［J］. J Biomed Biotechnol，2011，2011：451694. regulator of glucocorticoid resistance［J］. J Clin Endocrinol
DOI：10.1155/2011/451694. Metab，2016，101（8）：3123-3133. DOI：10.1210/jc.2016-
［35］KEIR M E，BUTTE M J，FREEMAN G J，et al. PD-1 1379.
and its ligands in tolerance and immunity［J］. Annu Rev ［48］ZHANG D，BERGSNEIDER M，WANG M B，et al. Targeting
Immunol，2008，26：677-704. DOI：10.1146/annurev. the ERK pathway for the treatment of Cushing's disease［J］.
immunol.26.021607.090331. Oncotarget，2016，7（43）：69149-69158. DOI：10.18632/
［36］WANG P F，WANG T J，YANG Y K，et al. The expression profile oncotarget.12381.
+
of PD-L1 and CD 8 lymphocyte in pituitary adenomas indicating for （收稿日期：2021-09-14；修回日期：2021-11-02）
immunotherapy［J］. J Neurooncol，2018，139（1）：89-95. （本文编辑：崔莎）